Cargando…
Current position of 5HT(3) antagonists and the additional value of NK(1) antagonists; a new class of antiemetics
The advent of the 5HT(3) receptor antagonists (5HT(3) antagonists) in the 1990 s and the combination with dexamethasone has resulted in acute emesis protection in 70% of patients receiving highly emetogenic chemotherapy. Despite complete protection in the acute phase, however, 40% of patients as yet...
| Autor principal: | |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2003
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2741127/ https://www.ncbi.nlm.nih.gov/pubmed/12799621 http://dx.doi.org/10.1038/sj.bjc.6601033 |